Sanofi (Sanofi) Change In Payables And Accrued Expense : $361 Mil (TTM As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi Change In Payables And Accrued Expense?

Sanofi's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2023 was $0 Mil. It means Sanofi's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Jun. 2023 .

Sanofi's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $438 Mil. It means Sanofi's Accounts Payable & Accrued Expense increased by $438 Mil from Dec. 2022 to Dec. 2023 .

Sanofi Change In Payables And Accrued Expense Historical Data

The historical data trend for Sanofi's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Change In Payables And Accrued Expense Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

187.78

104.62

509.61

478.81

438.39

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	117.34	361.23	-	-

Sanofi Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $361 Mil.

Sanofi Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Sanofi's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.